Zydus Lifesciences Q4 Profit Surges 4-Fold to Rs 1,182 cr
By Rediff Money Desk, New Delhi May 17, 2024 17:45
Zydus Lifesciences' net profit for the fourth quarter ended March 31, 2024, jumped four-fold to Rs 1,182 crore on higher sales. Revenue also rose to Rs 5,534 crore.
![Zydus Lifesciences Q4 Profit Surges 4-Fold to Rs 1,182 cr](https://im.rediff.com/money/2023/mar/31zydus.jpg)
Photograph: Courtesy Zydus.
New Delhi, May 17 (PTI) Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales.
The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.
Revenue from operations rose to Rs 5,534 crore in the period under review from Rs 5,011 crore in the year-ago period, Zydus Lifesciences said in a statement.
For the year ended March 31, 2024, the company reported a consolidated net profit of Rs 3,859 crore as compared with Rs 1,960 crore in FY23. Revenue from operations rose to Rs 19,547 crore from Rs 17,237 crore in the 2022-23 fiscal.
"Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well," Zydus Lifesciences MD Sharvil Patel said.
The company said its board has approved a final dividend of Rs 3 per equity share of Re 1 each, subject to approval of the shareholders.
Shares of the company ended 4.28 per cent up at Rs 1,051.90 apiece on the BSE.
The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.
Revenue from operations rose to Rs 5,534 crore in the period under review from Rs 5,011 crore in the year-ago period, Zydus Lifesciences said in a statement.
For the year ended March 31, 2024, the company reported a consolidated net profit of Rs 3,859 crore as compared with Rs 1,960 crore in FY23. Revenue from operations rose to Rs 19,547 crore from Rs 17,237 crore in the 2022-23 fiscal.
"Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well," Zydus Lifesciences MD Sharvil Patel said.
The company said its board has approved a final dividend of Rs 3 per equity share of Re 1 each, subject to approval of the shareholders.
Shares of the company ended 4.28 per cent up at Rs 1,051.90 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![Navi Mumbai...](https://im.rediff.com/80-80/money/2021/jun/10navi-mumbai-airport7.jpg)
Navi Mumbai Airport ILS Signal Testing Begins
The Airports Authority of India (AAI) has begun ILS signal testing at the...
![Air India VRS for...](https://im.rediff.com/80-80/money/2020/sep/09tata-vistara-3.jpg)
Air India VRS for Non-Flying Staff Ahead of...
Air India has announced a voluntary retirement scheme (VRS) and voluntary separation...
Fisher Groups Oppose WTO Fisheries Subsidy Talks
Small-scale fisher groups from India, Indonesia, and Bangladesh demand WTO keep...